Key result
Adjunctive treatment with Danshen and Gegen for 24 weeks significantly improved brachial flow-mediated dilation (p<0.001) and carotid intima-media thickness (p<0.05) in coronary patients.
Why the study?
Does adjunctive treatment with Salvia miltiorrhiza and Pueraria lobata improve brachial flow-mediated dilation and carotid intima-media thickness in coronary patients?
RCT (n=100)
Double-blind
randomized
Does adjunctive treatment with Salvia miltiorrhiza and Pueraria lobata improve brachial flow-mediated dilation and carotid intima-media thickness in coronary patients?
p-value: p=<0.001
Adjunctive treatment with Salvia miltiorrhiza and Pueraria lobata improved vascular function and structure as measured by brachial FMD and carotid IMT in coronary patients.
May support adjunctive use for vascular surrogates in coronary disease; extends complementary medicine evidence via RCT.
BACKGROUND: Danshen and gegen (D&G) have long been used in treatment of angina and other cardiac symptoms in Chinese materia medica. Recent pharmacological studies suggest their therapeutic values. We aimed to evaluate the efficacy and safety of Salvia miltiorrhiza (danshen) and Pueraria lobata (gegen) in secondary prevention. METHODS: One hundred (100) consecutive coronary patients (mean age 58 +/- 8 years) were randomized to adjunctive treatment with D&G combination (3 g) or placebo (6 capsules) for 24 weeks in double-blind parallel fashion, followed by optional open-label D&G (1.5 g/day) for 6 more months. Brachial flow-mediated dilation (FMD) and carotid intima-media thickness (IMT) were measured using ultrasound. RESULTS: Baseline characteristics were similar between the 2 groups. After 24 weeks and compared with baseline, there were no significant changes in blood pressures, blood hematological and biochemical profiles, or folate and homocysteine levels in both groups, but there was a mild decrease in low density lipoprotein (LDL) cholesterol in both groups (p < 0.05). Brachial FMD improved during D&G (p < 0.001) and less so during placebo treatment (p < 0.05), while improvement in carotid IMT was observed only in the D&G group (p < 0.05). After open-label D&G treatment for 6 more months (n = 45), further improvement in both brachial FMD (p < 0.0001) and carotid IMT (p < 0.0001) was observed. Eight (8) adverse events were reported-6 during placebo and 2 during D&G treatment-requiring treatment termination in 2 patients (on placebo). CONCLUSIONS: D&G adjunctive treatment in coronary patients was well tolerated and effective in improving vascular function and structure. These two herbs may become a novel agent for secondary prevention.
No takes yet. Share an insight, caveat, or question.
Tam et al. (2009) conducted an RCT in Coronary patients (n=100). Salvia miltiorrhiza (danshen) and Pueraria lobata (gegen) combination vs. Placebo was evaluated on Brachial flow-mediated dilation (FMD) and carotid intima-media thickness (IMT) (p=<0.001). Adjunctive treatment with Danshen and Gegen for 24 weeks significantly improved brachial flow-mediated dilation (p<0.001) and carotid intima-media thickness (p<0.05) in coronary patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: